Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068308 | 1.00 | MAPT (0.41) | MAPTLMNAHTTCYP1A2CYP3A4 | |
| SCHEMBL3927848 | 0.87 | ALDH1A1 (0.49) | MAPTLMNAHTTCYP1A2CYP3A4 | |
| SCHEMBL3927852 | 0.87 | ALDH1A1 (0.49) | MAPTLMNAHTTCYP1A2CYP3A4 | |
| SCHEMBL3927057 | 0.79 | BLM (0.44) | CYP2C9NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL3927053 | 0.79 | BLM (0.44) | CYP2C9NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL3927124 | 0.77 | RAB9A (0.44) | MAPTLMNAHTTNPC1RAB9A | |
| SCHEMBL3927119 | 0.77 | RAB9A (0.44) | MAPTLMNAHTTNPC1RAB9A | |
| SCHEMBL5580136 | 0.76 | RAB9A (0.50) | MAPTLMNAHTTNPC1RAB9A | |
| SCHEMBL3936107 | 0.76 | NPC1 (0.49) | MAPTLMNAHTTNPC1RAB9A | |
| SCHEMBL3936101 | 0.76 | NPC1 (0.49) | MAPTLMNAHTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420424-B1 | ADMINISTERING PHENYLALANINE AMIDE DERIVATIVES (SUCH AS S-ETHYL-2-AMINO-3-(4-CHLOROPHENYL)PROPIONATE HYDROCHLORIDE) TO TREAT ALLERGIC DISORDERS, INCLUDING ASTHMA, RHINITIS, DERMATITUS, AND PRURITIS | SMITHKLINE BEECHAM CORPORATION | 2002-07-16 | — | — | US | claimed |
| JP-2002512960-A | — | — | 2002-05-08 | — | — | JP | claimed |
| EP-1073434-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999055330-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-04 | — | — | WO | claimed |
| EP-1691199-B1 | METHOD OF PREDICTING SPOT FORMATION ON THE SKIN WITH THE USE OF SPOT SITE-ACCELERATING GENES AS INDICATION AND METHOD OF SCREENING INHIBITOR FOR SPOT FORMATION ON THE SKIN | SHISEIDO CO LTD (JP) | 2009-04-01 | — | — | EP | disclosed |
| US-20070249915-A1 | Inhibitors | SHISEIDO COMPANY, LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1691199-A1 | METHOD OF PREDICTING SPOT FORMATION ON THE SKIN WITH THE USE OF SPOT SITE-ACCELERATING GENES AS INDICATION AND METHOD OF SCREENING INHIBITOR FOR SPOT FORMATION ON THE SKIN | SHISEIDO COMPANY LIMITED (JP) | 2006-08-16 | — | — | EP | disclosed |
| US-6420424-B1 | ADMINISTERING PHENYLALANINE AMIDE DERIVATIVES (SUCH AS S-ETHYL-2-AMINO-3-(4-CHLOROPHENYL)PROPIONATE HYDROCHLORIDE) TO TREAT ALLERGIC DISORDERS, INCLUDING ASTHMA, RHINITIS, DERMATITUS, AND PRURITIS | SMITHKLINE BEECHAM CORPORATION | 2002-07-16 | — | — | US | disclosed |
| EP-1073434-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055330-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-04 | — | — | WO | disclosed |